See more : Caleffi S.p.A. (CLF.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genomma Lab Internacional, S.A.B. de C.V., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fintech Acquisition Corp. V (FTCVW) Income Statement Analysis – Financial Results
- Clean Vision Corporation (CLNV) Income Statement Analysis – Financial Results
- Valor Holdings Co., Ltd. (9956.T) Income Statement Analysis – Financial Results
- Elektrocieplownia Bedzin S.A. (BDZ.WA) Income Statement Analysis – Financial Results
- Endeavor Bancorp (EDVR) Income Statement Analysis – Financial Results
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.genommalab.com
About Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 969.48M | 862.36M | 754.10M | 696.10M | 673.21M | 598.89M | 617.33M | 549.30M | 639.36M |
| Cost of Revenue | 375.96M | 341.27M | 288.44M | 265.09M | 251.92M | 208.74M | 205.82M | 180.53M | 225.54M |
| Gross Profit | 593.52M | 521.09M | 465.65M | 431.01M | 421.29M | 390.15M | 411.52M | 368.77M | 413.82M |
| Gross Profit Ratio | 61.22% | 60.43% | 61.75% | 61.92% | 62.58% | 65.15% | 66.66% | 67.13% | 64.72% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.84B | 6.92B | 6.57B | 5.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -6.43B | -6.57B | -6.25B | -5.38B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 404.67M | 354.91M | 319.92M | 284.36M | 300.86M | 279.11M | 283.80M | 359.55M | 417.80M |
| Other Expenses | 420.19K | 3.17M | 192.92K | 588.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 404.67M | 351.74M | 319.73M | 283.77M | 300.86M | 279.11M | 283.80M | 359.55M | 417.80M |
| Cost & Expenses | 780.52M | 693.01M | 608.17M | 548.86M | 552.77M | 487.85M | 489.62M | 540.08M | 643.34M |
| Interest Income | 156.93M | 6.05M | 3.19M | 1.58M | 1.52M | 1.61M | 2.05M | 1.61M | 1.19M |
| Interest Expense | 829.90M | 26.95M | 21.64M | 23.14M | 32.13M | 28.16M | 24.71M | 16.02M | 22.73M |
| Depreciation & Amortization | 13.38M | 11.64M | 8.29M | 7.98M | 7.53M | 4.12M | 3.57M | 4.07M | 6.85M |
| EBITDA | 166.99M | 180.99M | 142.52M | 155.22M | 118.10M | 118.57M | 131.28M | -56.82M | -943.89M |
| EBITDA Ratio | 17.23% | 20.99% | 20.45% | 22.30% | 19.01% | 19.23% | 21.27% | 2.42% | 0.45% |
| Operating Income | 188.96M | 169.35M | 145.92M | 147.24M | 120.44M | 111.04M | 127.72M | 9.22M | -3.98M |
| Operating Income Ratio | 19.49% | 19.64% | 19.35% | 21.15% | 17.89% | 18.54% | 20.69% | 1.68% | -0.62% |
| Total Other Income/Expenses | 1.53B | -54.81M | -33.33M | -38.29M | -44.83M | -30.82M | -20.76M | 3.52M | -28.32M |
| Income Before Tax | 1.72B | 114.54M | 112.59M | 108.95M | 78.44M | 86.28M | 107.99M | -76.90M | -84.92M |
| Income Before Tax Ratio | 177.48% | 13.28% | 14.93% | 15.65% | 11.65% | 14.41% | 17.49% | -14.00% | -13.28% |
| Income Tax Expense | 635.67M | 44.48M | 44.50M | 38.49M | 42.14M | 33.21M | 38.78M | 6.14M | -21.65M |
| Net Income | 63.89M | 71.22M | 63.68M | 70.44M | 40.48M | 56.34M | 65.38M | -81.59M | -61.87M |
| Net Income Ratio | 6.59% | 8.26% | 8.44% | 10.12% | 6.01% | 9.41% | 10.59% | -14.85% | -9.68% |
| EPS | 0.07 | 0.07 | 0.06 | 0.07 | 0.04 | 0.06 | 0.07 | -0.08 | -0.06 |
| EPS Diluted | 0.07 | 0.07 | 0.06 | 0.07 | 0.04 | 0.06 | 0.07 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 957.34M | 993.23M | 1.01B | 1.01B | 1.01B | 1.02B | 952.49M | 980.81M | 1.03B |
| Weighted Avg Shares Out (Dil) | 957.34M | 993.23M | 1.01B | 1.01B | 1.01B | 1.02B | 952.49M | 980.81M | 1.03B |
Genomma Lab Internacional Announces Results for the Third Quarter 2024
Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2024 Earnings Results Conference Call
GENOMMA LAB PHARMA MANUFACTURING FACILITY GRANTED PENDING GMP CERTIFICATION FOR THE MEXICAN MARKET
GENOMMA LAB INTERNACIONAL ANNOUNCES NINTH DIVIDEND PAYMENT
Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands
GENOMMA LAB ANNOUNCES REFINANCING OF LONG-TERM LIABILITIES AND RELEASE OF REAL ESTATE COLLATERAL
Genomma Lab Internacional S.A.B. de C.V. Second Quarter 2024 Earnings Results Conference Call
GENOMMA LAB INTERNACIONAL ANNOUNCES EIGHTH DIVIDEND PAYMENT
Genomma Lab Internacional Announces Results for the First Quarter 2024
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
Source: https://incomestatements.info
Category: Stock Reports